Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry

Evelien J M de Jong; Irene Mommers; Arantza Fariña Sarasqueta; Lydia G van der Geest; Lara Heij; Ignace H J T de Hingh; Marjolein Y V Homs; Vivianne C G Tjan-Heijnen; Liselot B J Valkenburg-van Iersel; Johanna W Wilmink; Sandra M E Geurts; Judith de Vos-Geelen; Dutch Pancreatic Cancer Group

doi:10.1080/0284186x.2022.2053199

Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry

Evelien J M de Jong, Irene Mommers, Arantza Fariña Sarasqueta, Lydia G van der Geest, Lara Heij, Ignace H J T de Hingh, Marjolein Y V Homs, Vivianne C G Tjan-Heijnen, Liselot B J Valkenburg-van Iersel, Johanna W Wilmink, Sandra M E Geurts, Judith de Vos-Geelen^*, Dutch Pancreatic Cancer Group

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	591-596
Number of pages	6
Journal	Acta Oncologica
Volume	61
Issue number	5
Early online date	5 Apr 2022
DOIs	https://doi.org/10.1080/0284186x.2022.2053199
Publication status	Published - 4 May 2022

Keywords

ADENOCARCINOMA
CLINICAL-PRACTICE GUIDELINES
PANCREATIC-CANCER
THERAPY

Access to Document

10.1080/0284186x.2022.2053199

Cite this

de Jong, E. J. M., Mommers, I., Fariña Sarasqueta, A., van der Geest, L. G., Heij, L., de Hingh, I. H. J. T., Homs, M. Y. V., Tjan-Heijnen, V. C. G., Valkenburg-van Iersel, L. B. J., Wilmink, J. W., Geurts, S. M. E., de Vos-Geelen, J., & Dutch Pancreatic Cancer Group (2022). Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta Oncologica, 61(5), 591-596. https://doi.org/10.1080/0284186x.2022.2053199

@article{6c8131576c21426889b2fa5753cbf692,

title = "Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry",

keywords = "ADENOCARCINOMA, CLINICAL-PRACTICE GUIDELINES, PANCREATIC-CANCER, THERAPY",

author = "{de Jong}, {Evelien J M} and Irene Mommers and {Fari{\~n}a Sarasqueta}, Arantza and {van der Geest}, {Lydia G} and Lara Heij and {de Hingh}, {Ignace H J T} and Homs, {Marjolein Y V} and Tjan-Heijnen, {Vivianne C G} and {Valkenburg-van Iersel}, {Liselot B J} and Wilmink, {Johanna W} and Geurts, {Sandra M E} and {de Vos-Geelen}, Judith and {Dutch Pancreatic Cancer Group}",

note = "Funding Information: This work was not supported by the industry. As is stated in the disclosure, some authors did receive funding or personal fees from one or more third parties. This was all OUTSIDE the submitted and accepted work. No funding was received for this study. The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry as well as the IKNL staff for scientific advice. Funding Information: JDV has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, and has received institutional research funding from Servier. All outside the submitted work; Funding Information: SG reports grants from Roche, grants from Pfizer, grants from Novartis, grants from Lilly, grants from Daiichi Sankyo, grants from Gilead, personal fees from AstraZeneca. All outside the submitted work; Funding Information: JW reports grants and non-financial support from Servier, non-financial support from MSD, non-financial support from AstraZeneca, grants and non-financial support from Celgene, grants from Halozyme, grants from Merck, grants from Roche, grants from Pfizer, grants from Amgen, grants from Novartis. All outside the submitted work; Funding Information: VT-H reports grants and personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants and personal fees from Lilly, personal fees from Accord Healthcare, grants from AstraZeneca, grants from Eisai, grants from Daiichi Sankyo, grants from Gilead. All outside the submitted work; ",

year = "2022",

month = may,

day = "4",

doi = "10.1080/0284186x.2022.2053199",

language = "English",

volume = "61",

pages = "591--596",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Routledge/Taylor & Francis Group",

number = "5",

}

de Jong, EJM, Mommers, I, Fariña Sarasqueta, A, van der Geest, LG, Heij, L, de Hingh, IHJT, Homs, MYV, Tjan-Heijnen, VCG , Valkenburg-van Iersel, LBJ, Wilmink, JW, Geurts, SME , de Vos-Geelen, J & Dutch Pancreatic Cancer Group 2022, 'Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry', Acta Oncologica, vol. 61, no. 5, pp. 591-596. https://doi.org/10.1080/0284186x.2022.2053199

Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. / de Jong, Evelien J M; Mommers, Irene; Fariña Sarasqueta, Arantza et al.
In: Acta Oncologica, Vol. 61, No. 5, 04.05.2022, p. 591-596.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer

T2 - a short report from a nationwide registry

AU - de Jong, Evelien J M

AU - Mommers, Irene

AU - Fariña Sarasqueta, Arantza

AU - van der Geest, Lydia G

AU - Heij, Lara

AU - de Hingh, Ignace H J T

AU - Homs, Marjolein Y V

AU - Tjan-Heijnen, Vivianne C G

AU - Valkenburg-van Iersel, Liselot B J

AU - Wilmink, Johanna W

AU - Geurts, Sandra M E

AU - de Vos-Geelen, Judith

AU - Dutch Pancreatic Cancer Group

N1 - Funding Information: This work was not supported by the industry. As is stated in the disclosure, some authors did receive funding or personal fees from one or more third parties. This was all OUTSIDE the submitted and accepted work. No funding was received for this study. The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry as well as the IKNL staff for scientific advice. Funding Information: JDV has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, and has received institutional research funding from Servier. All outside the submitted work; Funding Information: SG reports grants from Roche, grants from Pfizer, grants from Novartis, grants from Lilly, grants from Daiichi Sankyo, grants from Gilead, personal fees from AstraZeneca. All outside the submitted work; Funding Information: JW reports grants and non-financial support from Servier, non-financial support from MSD, non-financial support from AstraZeneca, grants and non-financial support from Celgene, grants from Halozyme, grants from Merck, grants from Roche, grants from Pfizer, grants from Amgen, grants from Novartis. All outside the submitted work; Funding Information: VT-H reports grants and personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants and personal fees from Lilly, personal fees from Accord Healthcare, grants from AstraZeneca, grants from Eisai, grants from Daiichi Sankyo, grants from Gilead. All outside the submitted work;

PY - 2022/5/4

Y1 - 2022/5/4

KW - ADENOCARCINOMA

KW - CLINICAL-PRACTICE GUIDELINES

KW - PANCREATIC-CANCER

KW - THERAPY

U2 - 10.1080/0284186x.2022.2053199

DO - 10.1080/0284186x.2022.2053199

M3 - Comment/Letter to the editor

C2 - 35382678

SN - 0284-186X

VL - 61

SP - 591

EP - 596

JO - Acta Oncologica

JF - Acta Oncologica

IS - 5

ER -